- Home
- HTO vs NRIX Comparison
HTO vs NRIX Comparison
Compare HTO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | NRIX |
|---|---|---|
| Founded | 1985 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HTO | NRIX |
|---|---|---|
| Price | $47.94 | $18.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | ★ $58.00 | $26.50 |
| AVG Volume (30 Days) | 401.6K | ★ 1.6M |
| Earning Date | 10-27-2025 | 10-09-2025 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ 14.49 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $804,224,000.00 | $83,687,000.00 |
| Revenue This Year | $9.75 | $58.38 |
| Revenue Next Year | $8.19 | N/A |
| P/E Ratio | $15.09 | ★ N/A |
| Revenue Growth | 11.39 | ★ 48.32 |
| 52 Week Low | $43.75 | $8.18 |
| 52 Week High | $57.17 | $22.95 |
Technical Indicators
Market Signals| Indicator | HTO | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.74 | 74.70 |
| Support Level | $43.75 | $16.02 |
| Resistance Level | $48.42 | $17.79 |
| Average True Range (ATR) | 1.15 | 1.09 |
| MACD | 0.34 | 0.16 |
| Stochastic Oscillator | 90.04 | 96.31 |
Price Performance
Historical ComparisonAbout HTO H2O America Common Stock
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.